Cannabis Bioscience International Holdings, Inc. (CBIH) announced that a federal executive order signed by President Donald Trump on December 18, 2025, directs the Attorney General to expedite the Drug Enforcement Administration’s (DEA) rule‑making process to move marijuana from Schedule I to Schedule III. The order does not complete the reclassification; it merely accelerates the necessary regulatory steps, which are expected to be finalized in the coming months.
The executive order also expands federal research authority and grants Medicare access to cannabidiol (CBD) products, signaling a broader shift toward recognizing cannabis’s medical value. For CBIH, the move to Schedule III removes the drug’s “no accepted medical use” designation, opening the door to larger research contracts, easier clinical trial approvals, and potential tax relief by eliminating the IRS Code Section 280E limitation that currently bars deductions for ordinary business expenses.
CBIH’s Treasurer and Director John Jones said the rescheduling transforms the company’s long‑term vision from a hypothetical future into a tangible present. He noted that the new schedule will enable the firm to partner more readily with pharmaceutical companies, expand its medical‑cannabis education platform, and accelerate the development of medical formulations that are currently under review. The company’s focus on scientific discipline, intellectual property, and educational initiatives positions it to capitalize on the expanded research and commercial opportunities that Schedule III will create.
Financially, CBIH has faced significant volatility, with its stock trading at a low of $0.0005 in late December 2025. While the company’s revenue and earnings figures are not disclosed in the announcement, the regulatory shift is expected to improve cash flow by allowing the firm to deduct ordinary expenses and to attract new investment from institutional investors who previously avoided Schedule I companies.
The announcement comes after a series of milestones: the Department of Health and Human Services recommended Schedule III in August 2023, the Department of Justice proposed a rule in May 2024, and the executive order now clears the remaining bureaucratic hurdles. Analysts view the development as a positive tailwind for CBIH’s growth strategy, though the company must still navigate the final DEA rule‑making and potential state‑level regulatory variations.
Overall, the federal momentum toward rescheduling represents a significant regulatory win for CBIH, potentially unlocking new revenue streams, improving tax efficiency, and enhancing the firm’s competitive position in the evolving cannabis‑science market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.